Telecom Signaling Industry News

TMCNet:  Study on Generic HIV Meds Prompts AHF to Demand Gilead Cut ARV Prices

[January 15, 2013]

Study on Generic HIV Meds Prompts AHF to Demand Gilead Cut ARV Prices

WASHINGTON --(Business Wire)--

A new study published in the Annals of Internal Medicine today that provides a snapshot of a simplified cost/benefit analysis of the potential economic savings gained by use of generic antiretroviral therapy to treat people with HIV/AIDS versus the slightly reduced efficacy of the drugs prompted advocates from AIDS Healthcare Foundation (AHF) to reiterate its call on Gilead Sciences, a key maker of branded AIDS drugs, to reduce pricing on its key AIDS drugs such as Atripla and Stribild as patents expire. The study reported that billions of dollars in healthcare cost savings could be achieved through the use of generic antiretroviral therapy; however, the study also reported slightly reduced efficacy of the generic drugs.

"The differences in efficacy of the rugs reported in this study are largely a result of pill burden, because patients must often take the generic drugs separately and/or at more than one time per day versus the all-in-one, once-a-day convenience of many branded combinations like Gilead's Atripla," said Michael Weinstein, President of AIDS Healthcare Foundation. "However, these generic medications are still clearly effective, as evidenced by the success of global AIDS programs which have provided lifesaving treatment using generic drugs to millions of people in Africa and elsewhere in the developing world."

According to a BBC News story on the study, "…trial data suggests generic drugs might be slightly less effective. And they require users to take three daily pills instead of one, increasing the risk some patients may miss doses. The doctors calculate reduced treatment efficacy could result in 4.4 months of life lost per patient lifetime. At the same time the lifetime financial savings would be $42,500 (£26,500) per patient, say the Massachusetts General Hospital investigators."

"The savings could be as much as one billion dollars per year here in the United States, while the efficacy decreased relatively slightly when using generics," added AHF's Weinstein. "Now that Gilead's patents on many key drugs are expiring, the company must lower its prices of drugs like Atripla, Stribild-a four-in-one combination that actually relies on many older Gilead drugs that were otherwise approaching end of patent. In addition, we strongly believe that local, state, and federal governments should use every tool at their disposal to bring down drug prices. As tax dollars ultimately pay for most of these drugs, we extend our call on Gilead for price concessions on these AIDS drugs."

Stribild, Gilead's four-in-one AIDS treatment combination, was approved by the Food and Drug Administration (FDA) in early September and immediately priced by Gilead at $28,500 per patient, per year, Wholesale Acquisition Cost (WAC (News - Alert)). That price was over 35% more than Atripla, the company's best selling combination HIV/AIDS treatment, and made Stribild the highest priced first line combination AIDS therapy today.

About AIDS Healthcare Foundation

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to more than 183,000 individuals in 28 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website:, find us on Facebook (News - Alert): and follow us on Twitter (News - Alert): @aidshealthcare.

[ Back To Telecom Signaling's Homepage ]

Featured Events

5G NA Signaling Day

November 14-16, 2016
Sheraton Dallas, Dallas, TX

Featured Webcasts

Securing The Signaling Interconnect: Oracle's Perspective On Recent Security Events

Today's telecommunications landscape is changing rapidly, and the "institution" of trust between networks that has been assumed over the decades is no longer relevant. We are now hearing of vulnerabilities in CSP interconnection points that have been known ...

Applications of Wi-Fi Calling

With all of the discussion about faster data access and richer content, it could be assumed that voice services no longer play an important role in the business model of the communications service provider. Join ReThink Technologies Research and Oracle Communications as we explore ...

Featured Whitepapers

Oracle Communications Diameter Signaling Router Main Differentiators

Diameter is the protocol used by network elements in LTE and 3G networks to enable and monetize services, such as voice, video and data. Diameter enables revenue-generating data services; including tiered data plans, loyalty programs, application specific QoS, content provider and Internet of Things (IoT) solutions ...

Multi-Layer Security Protection for Signaling Networks

The sanctity of mobile operators' networks and brands will depend greatly on their ability to deliver QoS guarantees to roaming and interconnect partners, while simultaneously protecting increasingly multimedia-savvy and socially connected ...

Featured Datasheets

Oracle Communications Diameter Signaling Router

Centralizing Diameter routing with cloud deployable Oracle Communications Diameter Signaling Router creates a secure signaling architecture that reduces the cost and complexity of the core network and enables elastic growth, interoperability and rapid introduction ...

Oracle Communications Mobile Security Gateway

The Oracle Communications Mobile Security Gateway is a high performance gateway that allows the Communications Service Provider (CSP) to cost effectively expand network coverage and increase capacity by incorporating Heterogeneous ...

Oracle Communications Evolved Communications Application Server

As service providers drive their networks toward an all-IP and virtualized state, they require the means to design and deliver compelling high definition voice, video and multimedia offers via Voice over LTE (VoLTE) and Voice over WiFi (VoWiFi) ...

Featured Infographic